|  |  |  |  |
| --- | --- | --- | --- |
|  | **No. patients** | **Prevalence rate in total POSEIDON population (%)** | **Intra-group prevalence rate (%)** |
| **Overall POSEIDON population, N=5,639** |
| Group 1:*1a**1b* | 2,4932392,254 | 44.24.240.0 | -9.590.5 |
| Group 2:*2a**2b* | 2,0383151,723 | 36.15.630.5 | -15.584.5 |
| **Study Center 1 POSEIDON population, N=592** |
| Group 1:*1a**1b* | 12612114 | 21.32.119.2 | -9.590.5 |
| Group 2:*2a**2b* | 29277215 | 49.313.036.3 | -26.473.6 |
| **Study Center 2 POSEIDON population, N=1,783** |
| Group 1:*1a**1b* | 1,05187964 | 58.94.954.0 | -8.391.7 |
| Group 2:*2a**2b* | 53250482 | 29.82.827.0 | -9.490.6 |
| **Study Center 3 POSEIDON population, N=3,264** |
| Group 1:*1a**1b* | 1,3161401,176 | 40.34.336.0 | -10.689.4 |
| Group 2:*2a**2b* | 1,2141881,026 | 37.25.831.4 | -15.584.5 |

**Supplemental Table 2.** Prevalence rates of POSEIDON patients classified as subgroups ‘a’ and ‘b’ relative to the total POSEIDON population and within groups, overall and by study’s center.